Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026)
Harvard Bioscience (HBIO) reported EBITDA Margin of 5.66% for Q1 2026, up 22245.0% year-over-year from N/an in Q1 2025, and down 103.5% quarter-over-quarter from 161.48% in Q4 2025.
Harvard Bioscience (HBIO) EBITDA Margin (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of EBITDA Margin data on file, last reported at 5.66% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 5.66%, up 22245.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 42.71% (up 9724.0% YoY), and the FY2025 annual result was 13.82%, down 1122.0% from the prior year.
- EBITDA Margin retreated to 5.66% in Q1 2026 per HBIO's latest filing, from 161.48% in the prior quarter.
- Over five years, EBITDA Margin peaked at 161.48% in Q4 2025 and troughed at 228.11% in Q1 2025.
- A 5-year average of 5.71% and a median of 4.0% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 21881 bps in 2025, then soared 22245 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 16.0% in 2022, then slumped by 148 bps to 7.63% in 2023, then surged by 301 bps to 15.36% in 2024, then surged by 951 bps to 161.48% in 2025, then plunged by 104 bps to 5.66% in 2026.
- Business Quant data shows HBIO's EBITDA Margin at 5.66% in Q1 2026, 161.48% in Q4 2025, and 0.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 28.86% |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 1.97% |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 1.63% |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 34.92% |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 20.96% |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 4.04% |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -9.90% |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 13.65% |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 2.44% |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | -5.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.66% |
| Dec 31, 2025 | 161.48% |
| Sep 30, 2025 | 0.96% |
| Jun 30, 2025 | -4.00% |
| Mar 31, 2025 | -228.11% |
| Dec 31, 2024 | 15.36% |
| Sep 30, 2024 | -8.53% |
| Jun 30, 2024 | -8.96% |
| Mar 31, 2024 | -9.30% |
| Dec 31, 2023 | -7.63% |
| Sep 30, 2023 | -3.68% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | 5.83% |
| Dec 31, 2022 | 16.00% |
| Sep 30, 2022 | -13.97% |
| Jun 30, 2022 | 13.69% |
| Mar 31, 2022 | -23.32% |
| Dec 31, 2021 | 5.14% |
| Sep 30, 2021 | 1.85% |
| Jun 30, 2021 | 0.20% |